Musculoskeletal Research Laboratory, Division of Orthopaedic Surgery, St. Michael's Hospital, University of Toronto, 55 Queen St. E., Suite 800, Toronto, ON, M5C 1R6, Canada.
Knee Surg Sports Traumatol Arthrosc. 2012 Jul;20(7):1366-77. doi: 10.1007/s00167-012-1940-7. Epub 2012 Mar 9.
The purpose of this article was to analyze the results of studies in the literature, which evaluated the use of endothelial progenitor cells (EPCs) as a cell-based tissue engineering strategy.
EPCs have been successfully used in regenerative medicine to augment neovascularization in patients after myocardial infarction and limb ischemia. EPCs' important role as vasculogenic progenitors presents them as a potential source for cell-based therapies to promote bone healing.
EPCs have been shown to have prominent effects in promoting bone regeneration in several animal models. Evidence indicates that EPCs promote bone regeneration by stimulating both angiogenesis and osteogenesis through a differentiation process toward endothelial cell lineage and formation of osteoblasts. Moreover, EPCs increase vascularization and osteogenesis by increased secretion of growth factors and cytokines through paracrine mechanisms.
EPCs offer the potential to emerge as a new strategy among other cell-based therapies to promote bone regeneration. Further investigations and human trials are required to address current questions with regard to biology and mechanisms of action of EPCs in bone tissue engineering.
本文旨在分析文献中评估内皮祖细胞 (EPCs) 作为基于细胞的组织工程策略的应用效果的研究结果。
EPCs 已成功用于再生医学，以增加心肌梗死后和肢体缺血患者的新生血管形成。EPCs 作为血管生成祖细胞的重要作用使其成为促进骨愈合的细胞治疗的潜在来源。
几项动物模型研究表明，EPCs 在促进骨再生方面具有显著作用。有证据表明，EPCs 通过向内皮细胞谱系分化并形成成骨细胞，来促进血管生成和成骨，从而促进骨再生。此外，EPCs 通过旁分泌机制增加生长因子和细胞因子的分泌，从而增加血管生成和成骨。
EPCs 有望成为促进骨再生的另一种基于细胞的治疗策略。需要进一步的研究和人体试验来解决关于 EPCs 在骨组织工程中的生物学和作用机制的当前问题。
